OBJECTIVES: Aspirin is recommended for primary prevention in patients with metabolic syndrome (MetS). In this study, we evaluated aspirin resistance in MetS patients. STUDY DESIGN: The study included 32 patients (23 males, 9 females; mean age 60.7+/-11.4 years) with the diagnosis of MetS, according to the criteria of the International Diabetes Federation. Aspirin resistance was determined by the PFA-100 analysis (Platelet Function Analyzer). The results were compared with a control group of 30 patients (16 males, 14 females; mean age 61.6+/-7.3 years) without MetS. All the patients were taking aspirin at the time of the PFA-100 analysis. RESULTS: Overall, 21 patients (33.9%) were aspirin nonresponders. The prevalence of aspirin resistance was 46.9% in the MetS group, and 20% in the control group. The difference between the two groups was statistically significant (p=0.033). Compared to aspirin responders, fasting blood glucose level was higher (102.0+/-14.6 mg/dl vs. 95.3+/-9.9 mg/dl; p=0.036) and waist circumference tended to be greater in nonresponders (97.4+/-14.1 cm vs. 89.7+/-15.0 cm; p=0.053). Multivariate logistic regression analysis showed that MetS (OR 0.28, 95% CI 0.09-0.88; p=0.029), fasting blood glucose (OR 0.95, 95% CI 0.91-0.99; p=0.045), uric acid (OR 0.46, 95% CI 0.28-0.76; p=0.002), gamma-glutamyl transferase (OR 1.04, 95% CI 1.00-1.08; p=0.043), high-sensitivity C-reactive protein (OR 1.07, 95% CI 1.01-1.12; p=0.015) levels and platelet count (OR 0.99, 95% CI 0.98-0.99; p=0.034) significantly affected aspirin resistance. CONCLUSION: Our results show that a significant proportion of MetS patients will not benefit from aspirin use due to high aspirin resistance.
OBJECTIVES:Aspirin is recommended for primary prevention in patients with metabolic syndrome (MetS). In this study, we evaluated aspirin resistance in MetS patients. STUDY DESIGN: The study included 32 patients (23 males, 9 females; mean age 60.7+/-11.4 years) with the diagnosis of MetS, according to the criteria of the International Diabetes Federation. Aspirin resistance was determined by the PFA-100 analysis (Platelet Function Analyzer). The results were compared with a control group of 30 patients (16 males, 14 females; mean age 61.6+/-7.3 years) without MetS. All the patients were taking aspirin at the time of the PFA-100 analysis. RESULTS: Overall, 21 patients (33.9%) were aspirin nonresponders. The prevalence of aspirin resistance was 46.9% in the MetS group, and 20% in the control group. The difference between the two groups was statistically significant (p=0.033). Compared to aspirin responders, fasting blood glucose level was higher (102.0+/-14.6 mg/dl vs. 95.3+/-9.9 mg/dl; p=0.036) and waist circumference tended to be greater in nonresponders (97.4+/-14.1 cm vs. 89.7+/-15.0 cm; p=0.053). Multivariate logistic regression analysis showed that MetS (OR 0.28, 95% CI 0.09-0.88; p=0.029), fasting blood glucose (OR 0.95, 95% CI 0.91-0.99; p=0.045), uric acid (OR 0.46, 95% CI 0.28-0.76; p=0.002), gamma-glutamyl transferase (OR 1.04, 95% CI 1.00-1.08; p=0.043), high-sensitivity C-reactive protein (OR 1.07, 95% CI 1.01-1.12; p=0.015) levels and platelet count (OR 0.99, 95% CI 0.98-0.99; p=0.034) significantly affected aspirin resistance. CONCLUSION: Our results show that a significant proportion of MetS patients will not benefit from aspirin use due to high aspirin resistance.
Authors: James P Smith; Elias V Haddad; Mary B Taylor; Denise Oram; Dana Blakemore; Qingxia Chen; Olivier Boutaud; John A Oates Journal: Hypertension Date: 2012-02-06 Impact factor: 10.190
Authors: Nor Halwani Habizal; Sanihah Abdul Halim; Shalini Bhaskar; Wan Mohamed Wan Bebakar; Jafri Malin Abdullah Journal: Malays J Med Sci Date: 2015 Jan-Feb